Farr M, Brodrick A, Bacon P A
Department of Rheumatology, Medical School, University of Birmingham, UK.
Rheumatol Int. 1985;5(6):247-51. doi: 10.1007/BF00541351.
A study was made of plasma and synovial fluid levels of sulphasalazine, one of its dissociation products--sulphapyridine and a metabolite of the latter--acetyl sulphapyridine in patients with rheumatoid arthritis (RA) who were in a steady state on sulphasalazine therapy. Combined sulphapyridine levels were significantly higher than those of sulphasalazine both in plasma and synovial fluid. Synovial fluid levels of both drugs correlated with their plasma levels and were generally slightly lower. Some patients accumulated sulphasalazine and sulphapyridine in the synovial fluid and the mean concentration of sulphasalazine was higher in the fluid than in the plasma. The explanation for this is uncertain. The concentration of combined sulphapyridine in synovial fluid was related to local joint inflammation and more active systemic disease. No consistent association was found between sulphasalazine levels and local or systemic activity. The higher sulphapyridine levels in synovial fluid found in this study suggest the possibility that this moiety could play a more active role in RA than it does in inflammatory bowel disease.
对类风湿关节炎（RA）患者在柳氮磺胺吡啶治疗稳定期时血浆和滑液中柳氮磺胺吡啶、其解离产物之一磺胺吡啶以及磺胺吡啶的代谢产物乙酰磺胺吡啶的水平进行了研究。血浆和滑液中磺胺吡啶的总水平均显著高于柳氮磺胺吡啶的水平。两种药物的滑液水平与其血浆水平相关，且通常略低。一些患者在滑液中蓄积了柳氮磺胺吡啶和磺胺吡啶，滑液中柳氮磺胺吡啶的平均浓度高于血浆中的浓度。对此的解释尚不确定。滑液中磺胺吡啶的总浓度与局部关节炎症和更活跃的全身性疾病有关。未发现柳氮磺胺吡啶水平与局部或全身活动之间存在一致的关联。本研究中发现滑液中较高的磺胺吡啶水平提示该部分在类风湿关节炎中可能比在炎症性肠病中发挥更积极的作用。
